This is an aggregated industry headline. Read the full story at FiercePharma →
CSL slashes revenue projection and takes $5B impairment as interim CEO flags R&D misses, market erosion
CSL has slashed its revenue projection for the fiscal year from $15.8 billion to $15.2 billion, in another indication of the Australian company’s financial distress since its 2022 acquisition of Vifor Pharma for $11.7 billion. Additionally, the Australian company is writing off $5 billion in assets.
By FiercePharma
· May 12, 2026
· via FiercePharma
Image: FiercePharma
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
moneyformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Money
All Money →
MoneyBioPharma Dive ↗
Research Alliance III follows a few months after Cormorant Asset Management priced a $150 million IPO for its …
MoneyFierceBiotech ↗
If any proof was needed that big money is still available for AI drug development, look no further than the 10…
MoneyFierceBiotech ↗
Odyssey Therapeutics has become the latest biotech to voyage to the public markets via an upsized $304 million…